Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions

被引：9

作者：

Chen, Helen X. ^{[1
]}

Cleck, Jessica N. ^{[2
]}

Coelho, Rochelle ^{[2
]}

Dancey, Janet E. ^{[3
]}

机构：

[1] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Rockville, MD USA

[2] Tech Resources Int Inc, Bethesda, MD USA

[3] Ontario Inst Canc Res, Toronto, ON, Canada

来源：

CURRENT PROBLEMS IN CANCER | 2009年 / 33卷 / 04期

关键词：

CELL LUNG-CANCER; PHASE-II TRIAL; TYROSINE KINASE INHIBITOR; GENE COPY NUMBER; CETUXIMAB PLUS IRINOTECAN; REFRACTORY COLORECTAL-CANCER; PREVIOUSLY TREATED PATIENTS; 1ST-LINE TREATMENT; ACQUIRED-RESISTANCE; EGFR MUTATIONS;

D O I：

10.1016/j.currproblcancer.2009.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：245 / +

页数：51

共 180 条

[1] Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells [J].

Agarwal, S. ;

Zerillo, C. ;

Kolmakova, J. ;

Christensen, J. G. ;

Harris, L. N. ;

Rimm, D. L. ;

DiGiovanna, M. P. ;

Stern, D. F. .

BRITISH JOURNAL OF CANCER, 2009, 100 (06) :941-949

[2] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[3]

[Anonymous], J CLIN ONCOL S

[4]

[Anonymous], J CLIN ONCOL S

[5]

ARGIRIS A, 2009, J CLIN ONCOL, V27, pA6011

[6] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[7] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[8] Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors [J].

Bianco, R ;

Shin, I ;

Ritter, CA ;

Yakes, FM ;

Basso, A ;

Rosen, N ;

Tsurutani, J ;

Dennis, PA ;

Mills, GB ;

Arteaga, CL .

ONCOGENE, 2003, 22 (18) :2812-2822

[9] Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells [J].

Bianco, Roberto ;

Rosa, Roberta ;

Damiano, Vincenzo ;

Daniele, Gennaro ;

Gelardi, Teresa ;

Garofalo, Sonia ;

Tarallo, Valeria ;

De Falco, Sandro ;

Melisi, Davide ;

Benelli, Roberto ;

Albini, Adriana ;

Ryan, Anderson ;

Ciardiello, Fortunato ;

Tortora, Giampaolo .

CLINICAL CANCER RESEARCH, 2008, 14 (16) :5069-5080

[10]

BOKEMEYER C, 2007, ASCO M S, V25, P4035

← 1 2 3 4 5 6 7 8 9 10 →